N. Danny Shulman is an associate in the New York office of Latham & Watkins.

Mr. Shulman primarily handles capital markets transactions and public company representation, including representing issuers, underwriters, agents, and initial purchasers in initial and follow-on public equity offerings, ATM programs, and secured and unsecured high yield debt offerings.

Mr. Shulman’s experience includes representing: 

  • Sight Sciences
  • SQZ Biotechnologies
  • Atea Pharmaceuticals
  • Allegro MicroSystems
  • Frequency Therapeutics
  • MeiraGTx
  • BioXcel Therapeutics
  • Eloxx Pharmaceuticals
  • ContraFect Corporation
  • T2Biosystems
  • Underwriters and sales agents in equity offerings by Axcella Health, Addus Homecare, AdaptHealth, Clearway, Nanox
    Imaging, scPharmaceuticals, and Tecnoglass 
  • Initial Purchasers in unsecured and unsecured notes offerings, including green bonds and sustainability linked notes, by leading energy companies

Bar Qualification

  • New Jersey
  • New York
  • Pennsylvania


  • JD, University of Pennsylvania Law School, 2016
    Law Review, Wharton Certificate in Business Economics and Public Policy
  • BA/BS in Jewish Philosophy & Accounting, Yeshiva University, 2012
    summa cum laude